Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 5/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | TNKS | O95271 | 8/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.34 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29969684 | 1.00 | PRKDC (0.49) | PRKDCATMTNKSTNKS2IP6K1 | |
| SCHEMBL21851224 | 0.90 | PRKDC (0.42) | PRKDCATMTNKSTNKS2 | |
| SCHEMBL21512536 | 0.88 | PRKDC (0.40) | PRKDCATM | |
| SCHEMBL26132005 | 0.88 | PRKDC (0.40) | PRKDCATMTNKSTNKS2 | |
| SCHEMBL29969881 | 0.88 | PRKDC (0.40) | PRKDCATMTNKSTNKS2 | |
| SCHEMBL21512554 | 0.87 | PRKDC (0.40) | PRKDCATMTNKSTNKS2 | |
| SCHEMBL29969488 | 0.87 | PRKDC (0.41) | PRKDCATM | |
| SCHEMBL29968406 | 0.87 | PRKDC (0.41) | PRKDCATM | |
| SCHEMBL21512724 | 0.87 | PRKDC (0.41) | PRKDCATM | |
| SCHEMBL21513173 | 0.87 | PRKDC (0.41) | PRKDCATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | claimed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | claimed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | claimed |
| EP-3784671-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | claimed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | claimed |
| US-20250268873-A1 | COMBINATION OF DUAL ATM AND DNA-PK INHIBITORS AND IMMUNOTHERAPEUTIC AGENTS FOR USE IN CANCER THERAPY | XRAD THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4003345-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4288423-A1 | COMBINATION OF DUAL ATM AND DNA-PK INHIBITORS AND IMMUNOTHERAPEUTIC AGENTS FOR USE IN CANCER THERAPY | XRad Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2021022078-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | PRKDC 57/4885ATM 1/4885TNKS 41/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | PRKDC 57/4885ATM 1/4885TNKS 41/4885 |
| US-20250268873-A1 | COMBINATION OF DUAL ATM AND DNA-PK INHIBITORS AND IMMUNOTHERAPEUTIC AGENTS FOR USE IN CANCER THERAPY | ATM, CHEK2, CHEK1 | PRKDC 372/4885ATM 1/4885TNKS 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.